explore -WSS

explore

author：knowledge 2025-09-27 12:21:39 - browse：641

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Sickle cell gene therapy cures need to be accessible in Africa

WSS

One Duchenne patient's bittersweet hope for new treatment

Friends ask where James Watson's attitudes about race came from

How are insurers handling Leqembi and related scans?

Drastic changes should bring profitability, startup health insurers say

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

The best solution to the drug shortages problem

knowledge

explore

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Inflation cooled significantly in June, bringing price hikes close to normal levels

Activists slam private health insurers over coverage restrictions

In same hospitals, Black patients receive fewer opioids than white patients

Hollywood unions extend contract negotiations for actors

South Korea throws huge K

Duchenne breakthrough therapy leaves behind pioneering families

What to know about Virgin Galactic's 1st mission taking paying customers to space

BioMarin wins approval for gene therapy to treat hemophilia A

Why failed clinical trials don’t always spell doom for a new drug

focus

American woman, child freed after being kidnapped in Haiti last month

Inflation cooled significantly in June, bringing price hikes close to normal levels

EU fines Illumina $475 million over Grail acquisition

Grail's uphill battle for Medicare to cover its cancer screening test

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

Wegovy’s successful heart trial raises vital question about weight loss

explore

focus

entertainment

focus